ENHANCEMENT OF CYTOCHROME P-450 3A4 CATALYTIC ACTIVITIES BY CYTOCHROME b 5 IN BACTERIAL MEMBRANES

Size: px
Start display at page:

Download "ENHANCEMENT OF CYTOCHROME P-450 3A4 CATALYTIC ACTIVITIES BY CYTOCHROME b 5 IN BACTERIAL MEMBRANES"

Transcription

1 /99/ $02.00/0 DRUG METABOLISM AND DISPOSITION Vol. 27, No. 9 Copyright 1999 by The American Society for Pharmacology and Experimental Therapeutics Printed in U.S.A. ENHANCEMENT OF CYTOCHROME P-450 3A4 CATALYTIC ACTIVITIES BY CYTOCHROME b 5 IN BACTERIAL MEMBRANES HIROSHI YAMAZAKI, MIKI NAKAJIMA, MAMI NAKAMURA, SATORU ASAHI, NORIAKI SHIMADA, ELIZABETH M. J. GILLAM, F. PETER GUENGERICH, TSUTOMU SHIMADA, AND TSUYOSHI YOKOI Faculty of Pharmaceutical Sciences, Kanazawa University, Kanazawa, Japan (H.Y., M. Nakajima, M. Nakamura, M. Nakajima, T.Y.); Takeda Chemical Industries, Ltd., Osaka, Japan (S.A.); Daiichi Pure Chemicals Co., Ibaraki, Japan (N.S.); Department of Physiology and Pharmacology, University of Queensland, St. Lucia, Queensland, Australia (E.M.J.G.); Department of Biochemistry and Center in Molecular Toxicology, Vanderbilt University School of Medicine, Nashville, Tennessee (F.P.G.); and Osaka Prefectural Institute of Public Health, Osaka, Japan (T.S.) (Received March 9, 1999; accepted June 2, 1999) This paper is available online at ABSTRACT: Activities of testosterone, nifedipine, and midazolam oxidation by recombinant cytochrome P-450 (P-450) 3A4 coexpressed with human NADPH-P-450 reductase (NPR) in bacterial membranes (CYP3A4/NPR membranes) were determined in comparison with those of other recombinant systems and of human liver microsomes with high contents of CYP3A4. Growth conditions for Escherichia coli transformed with the bicistronic construct affected expression levels of CYP3A4 and NPR; an excess of NPR over P-450 in membrane preparations enhanced CYP3A4-dependent testosterone 6 -hydroxylation activities of the CYP3A4/NPR membranes. Cytochrome b 5 (b 5 ) and apolipoprotein b 5 further enhanced the testosterone 6 -hydroxylation activities of CYP3A4/NPR membranes after addition to either bacterial membranes or purified enzymes. NPR was observed to enhance catalytic activity when Multiple forms of cytochrome P-450 (P-450) 1 exist in mammals, and these P-450 enzymes play important roles in the oxidation of structurally diverse xenobiotic chemicals and endobiotics (Guengerich and Shimada, 1991; Guengerich, 1995; Nelson et al., 1996). P-450s are not self-sufficient enzymes, and the microsomal enzymes require a NADPH-P-450 reductase (NPR) as an electron carrier to function as monooxygenases. In human livers, levels of each of the P-450 forms are different and roles in various substrate oxidations vary. CYP3A4 is the major P-450 enzyme involved in the oxidation of a large number of compounds (Wrighton and Stevens, 1992; Gonzalez and Gelboin, 1994; Shimada et al., 1994). Recently, recombinant P-450 enzymes from different sources e.g., microsomes of human lymphoblastoid cells (Gonzalez et al., 1991; Crespi, 1995), yeast (Renaud et al., 1993; Imaoka et al., 1996), This work was supported in part by grants from the Japanese Ministries of Education, Science, Sports, and Cultures; and Health and Welfare. 1 Abbreviations used are: P-450, cytochrome P-450; NPR, NADPH-P-450 reductase; CYP3A4/NPR membranes, membranes prepared from bacteria coexpressing CYP3A4 and NPR from a bicistronic vector; apo b 5, apolipoprotein cytochrome b 5 ; LB, Luria-Bertani medium; TB, Terrific Broth. Send reprint requests to: Hiroshi Yamazaki, Ph.D., Division of Drug Metabolism, Faculty of Pharmaceutical Sciences, Kanazawa University, 13-1 Takaramachi, Kanazawa , Japan. yamazak@kenroku.kanazawa-u.ac.jp 999 added to the CYP3A4/NPR membranes, either in the form of bacterial membranes or as purified NPR (in combination with cholate and b 5 ). Apparent maximal activities of testosterone 6 -hydroxylation in CYP3A4/NPR membranes were obtained when the molar ratio of CYP3A4/NPR/b 5 was adjusted to 1:2:1 by mixing membranes containing each protein. Testosterone 6 -hydroxylation, nifedipine oxidation, and midazolam 4- and 1 -hydroxylation activities in CYP3A4/NPR membranes plus b 5 systems were similar to those measured with microsomes of insect cells coexpressing CYP3A4 with NPR and/or of human liver microsomes, based on equivalent CYP3A4 contents. These results suggest that CYP3A4/ NPR membrane systems containing b 5 are very useful models for prediction of the rates for liver microsomal CYP3A4-dependent drug oxidations. and insect cells infected with baculovirus systems (Buters et al., 1994; Lee et al., 1995) and reconstitution systems containing purified P-450 enzymes from Escherichia coli membranes (Gillam et al., 1993; Shaw et al., 1997) have been used widely for drug metabolism research. We have shown that a 1:2:1 molar ratio of CYP3A4/NPR/cytochrome b 5 (b 5 ) is optimal in the reconstitution of drug oxidation (Yamazaki et al., 1996b; Shimada and Yamazaki, 1998) using purified CYP3A4. However, the marker activities or kinetic parameters of CYP3A4 reported from different research laboratories and commercial enzymes manufacturers are not always similar. In this study, we have determined optimal catalytic activities for testosterone 6 -hydroxylation, nifedipine oxidation, and midazolam 4- and 1 -hydroxylation by CYP3A4/ NPR membranes (obtained using a bacterial bicistronic CYP3A4 expression system) fortified with b 5 or NPR and compared the activities of several types of recombinant CYP3A4 preparations before and after addition of b 5 and/or NPR. Enhancement of CYP3A4-dependent activities in membranes by addition of b 5 from different sources, apolipoprotein b 5 (apo b 5 ), and kinetic parameters for testosterone 6 -hydroxylation are also reported. Materials and Methods Chemicals. Midazolam and its metabolites were kindly donated by Yamanouchi Pharmaceuticals Co., Ltd. (Tokyo, Japan). Testosterone, nifedipine, and their metabolites and reagents used in this study were obtained from sources

2 1000 YAMAZAKI ET AL. TABLE 1 Catalytic activities for testosterone 6 -hydroxylation by several preparations of CYP3A4/NPR membranes obtained from E. coli transformed with a bicistronic CYP3A4/NPR expression vector a Culture Conditions CYP3A4/ NPR Preparation LB Time Medium TB Time rpm b CYP3A4 NPR NPR/CYP3A4 Testosterone 6 - Hydroxylation h h nmol/g cells nmol/liter culture nmol/g cells nmol/liter culture Molar ratio nmol/min/nmol CYP3A4 A B C D E F a The LB cultures were incubated for 7 to 15 h at 37 C with shaking at 170 rpm and then diluted 1:100 into TB. The TB cultures (100 ml) were grown at 30 C with shaking at 120 to 180 rpm for 24 to 32 h in 500-ml triple-baffled flasks. Results are presented as means of duplicate determinations. b Agitation speed (rpm) for TB culture. described previously or were of the highest qualities commercially available (Yamazaki et al., 1996b; Shimada and Yamazaki, 1998). Enzyme Preparations. Membranes were prepared from E. coli into which CYP3A4 and NPR cdnas had been introduced as described previously (Parikh et al., 1997). Briefly, single transformed colonies of E. coli strains DH5 and JM109 were used to inoculate starter Luria-Bertani medium (LB)/ ampicillin (25 g/ml) cultures. The starter cultures were incubated for 7 to 15 h at 37 C, with shaking at 170 rpm, and then diluted 1:100 into Terrific Broth (TB)/ampicillin (100 g/ml) medium containing additives (0.5 mm -aminolevulinic acid, 1.0 mm isopropyl -D-thiogalactoside, trace salts, and 1.0 mm thiamine; Guengerich et al., 1996). The expression cultures (100 ml) were grown at 30 C with shaking at 120 to 180 rpm for 24 to 32 h in 500-ml triple-baffled flasks. Membrane fractions were prepared from the bacterial pellets by a series of fractionation and high-speed centrifugation steps (Guengerich et al., 1996) and suspended in one volume of 10 mm Tris-HCl buffer (ph 7.4) containing 0.10 mm EDTA and 20% glycerol (v/v). Recombinant monocistronic CYP3A4, CYP1A2, and NPR were purified from membranes as described elsewhere (Gillam et al., 1993; Dong et al., 1996; Parikh et al., 1997). Rabbit NPR (Guengerich et al., 1981) and rabbit (Strittmatter et al., 1978), rat, and human b 5 (Shimada et al., 1986) were purified from liver microsomes by the methods described. Recombinant human NPR and b 5 were purified using similar methods. Apo b 5 was prepared from rabbit b 5 as described previously (Yamazaki et al., 1996a). Horse heart cytochrome c was purchased from Sigma. Human liver microsomes were prepared in 10 mm Tris-HCl buffer (ph 7.4) containing 0.10 mm EDTA and 20% glycerol (v/v) as described previously (Guengerich, 1994; Inoue et al., 1997). Recombinant CYP3A4 expressed in microsomes of insect cells infected with baculovirus containing human P-450 and rabbit or human NPR cdna inserts were obtained from PanVera (Madison, WI) or Gentest (Woburn, MA). Recombinant CYP3A4 in microsomes from lymphoblastoid cells coexpressing NPR was obtained from Gentest. The P-450 contents were used as described in the data sheets provided by the manufacturers. Enzyme Assays. Testosterone hydroxylation, nifedipine oxidation, and midazolam hydroxylation activities were determined as described (Kronbach et al., 1989; Brian et al., 1990) with slight modifications (Shimada and Yamazaki, 1998). The standard incubation mixture (final volume of 0.25 ml) contained M recombinant CYP3A4, M NPR, M b 5, and 100 mm potassium phosphate buffer (ph 7.4), an NADPH-generating system consisting of 0.5 mm NADP, 5 mm glucose 6-phosphate, and 0.5 U of glucose 6-phosphate dehydrogenase/ml, and 200 M testosterone (or nifedipine) or 100 M midazolam. In some cases, human liver microsomes were used at the same CYP3A4 concentrations as the recombinant system. Incubations were carried out at 37 C for 10 min and terminated by adding 1.5 ml of CH 2 Cl 2 and 0.3 M NaCl. Reactions with nifedipine were incubated at 37 C for 5 min and terminated by adding 1.5 ml of CH 2 Cl 2, 0.2 M NaCl, and 0.1 M Na 2 CO 3. Organic phases were evaporated under a nitrogen stream, and product formation was determined by HPLC with a C 18 (5- m) analytical column ( mm). Reactions with midazolam were incubated at 37 C for 5 min and terminated by adding 0.25 ml of CH 3 OH. The elution was conducted with a mixture of 64% CH 3 OH/36% H 2 O (v/v) at a flow rate of 1.2 ml/min, and the detection was by UV absorbance at 240 nm (testosterone) and 254 nm (nifedipine). The elution of midazolam metabolites was conducted with a mixture of 27% CH 3 OH/18% CH 3 CN/55% 10 mm potassium phosphate buffer (ph 7.4) (v/v) at a flow rate of 1.5 ml/min, and detection was by UV absorbance at 220 nm. Other Assays. Concentrations of P-450 and b 5 and protein were estimated spectrally by the described methods (Lowry et al., 1951; Omura and Sato, 1964). NADPH-cytochrome c reduction activities were determined as described (Williams and Kamin, 1962; Yasukochi and Masters, 1976) using mm 1 cm 1 and an assumed specific activity of 3.0 mol reduced cytochrome c/min/nmol NPR based on purified human and rabbit NPR preparations (Parikh et al., 1997). The contents of CYP3A4 in human liver microsomes were estimated by coupled SDS-polyacrylamide gel electrophoresis/immunochemical development (Western blotting) (Guengerich et al., 1982). Kinetic analyses for substrate oxidations by P-450 enzymes were estimated from the fitted curves using a computer program (KaleidaGraph program; Synergy Software, Reading, PA) designed for nonlinear regression analysis. Results Recovery of CYP3A4 and NPR in Membranes of E. coli. CYP3A4 and NPR were coexpressed in E. coli from a bicistronic vector using six different culture conditions (Table 1). With regard to CYP3A4 expression levels, long incubation for both LB and TB cultures with vigorous shaking resulted in good yields (Table 1, lot F). On the other hand, the final yield of NPR was highest when the culture time in LB was 7 h, followed by 32 h with mild shaking, in TB medium (Table 1, lot B). Catalytic activities of CYP3A4/NPR membranes for testosterone 6 -hydroxylation were higher in samples B and A. Effects of Exogenous b 5 and NPR on Catalytic Rates of CYP3A4/NPR Membranes. Because a 1.1:1 molar ratio of NPR/ CYP3A4 in membrane preparations appeared to give highest catalytic activities for CYP3A4-dependent testosterone 6 -hydroxylation among the conditions tested (Table 1), the effects of b 5 on activity were investigated mainly using this preparation. The effect of b 5 was shown to be concentration-dependent (Fig. 1A). Both human b 5 in E. coli membranes and purified recombinant human b 5 enhanced the testosterone hydroxylation activities about 2-fold; a1to2:1molar ratio of b 5 /CYP3A4 produced the highest activities. The effects of adding recombinant human NPR (in membranes) were studied. Rates of testosterone 6 -hydroxylation by recombinant CYP3A4 (lot B) were increased 2-fold by the supplementation with

3 TESTOSTERONE, NIFEDIPINE, AND MIDAZOLAM OXIDATION BY CYP3A FIG. 1.Concentration dependence of the effects of human b 5 and NPR in membranes on testosterone 6 -hydroxylation by CYP3A4/NPR membranes. A, testosterone (200 M) was incubated with CYP3A4/NPR membranes (Table 1, preparation B, M CYP3A4) fortified with membranes expressing human NPR (final, M) in the presence of recombinant human b 5 added in E. coli membranes (f) or as purified b 5 (Œ). B, testosterone (200 M) was incubated with CYP3A4/NPR membranes containing CYP3A4 (0.010 M) and recombinant human NPR (0.011 M) that were fortified further with different amounts of NPR, added in bacterial membranes to the final ratios shown, in the absence (E) or presence of added, purified human b 5 (Œ) orb 5 in membranes (f) (0.010 M). At the zero molar ratio of NPR to CYP3A4, E. coli membranes expressing only CYP3A4 were used. recombinant human NPR to an 8-fold excess of NPR over CYP3A4 in membranes in the absence of b 5 (Fig. 1B). In the presence of b 5, apparent optimal activities were observed after the addition of a 2:1 final molar ratio of NPR to CYP3A4 (Fig. 1B). Stimulating effects of b 5 also were observed upon addition of either rabbit, rat, or human b 5 purified from liver microsomes as well as recombinant human b 5 (Table 2). Apo b 5 and recombinant CYP1A2 also enhanced the catalytic activities of CYP3A4/NPR as well as b 5, but cytochrome c did not. Recombinant human NPR, purified from E. coli membranes, catalyzed NADPH-dependent cytochrome c reduction and supported CYP3A4-dependent testosterone 6 -hydroxylation (Table 3); however, purified human NPR-supported CYP3A4 activity for testosterone hydroxylation was lower in a reconstituted system containing a 1:2:1 molar ratio of CYP3A4/NPR/b 5 than was that supported by native rabbit NPR. The effects of supplementation with purified native rabbit NPR and cholate on CYP3A4 expressed in membranes were investigated (Fig. 2). Cholate enhanced dose-despondently the exogenous rabbit NPR-supported activities of CYP3A4/NPR membranes in the presence of b 5 (Fig. 2A). When purified native rabbit NPR was used, testosterone 6 -hydroxylation was improved in the presence of both b 5 and cholate (Fig. 2B). The apparent maximal activities were similar after addition of purified rabbit NPR ( 80 min 1 ) (Fig. 2B) and recombinant human NPR (in membranes) (Fig. 1B). Comparison of Bacterial CYP3A4/NPR Membranes with Other Recombinant Proteins and Human Liver Microsomes. To compare testosterone 6 -hydroxylation activities among recombinant CYP3A4 systems, we determined the rates of other recombinant CYP3A4 systems and human liver microsomes after addition of purified b 5 and/or NPR with cholate (Table 4). Catalytic activities of microsomes of lymphoblastoid cells were increased 3-fold by the addition of a 2-fold excess of b 5 over CYP3A4. However, the rates of this system fortified with NPR were lower than those obtained with CYP3A4 expressed using the bacterial CYP3A4/NPR membranes. The activities of one of the microsomal systems from insect cells with baculovirus systems (Baculosomes; PanVera) containing a 1:4.6 molar ratio of CYP3A4 to NPR were improved by the addition of a 2-fold excess of b 5 to CYP3A4. The activities of another baculovirus system containing CYP3A4/NPR/b 5 (1:12:16) (Supersomes; Gentest) were not TABLE 2 Effects of source of b 5 and other proteins on testosterone 6 -hydroxylation activities by CYP3A4/NPR membranes NPR Membrane Added Component Testosterone 6 -Hydroxylation nmol/min/nmol P-450 Experiment 1 CYP3A4/NPR 41 CYP3A4/NPR Recombinant 80 human b 5 CYP3A4/NPR Human b 5 78 CYP3A4/NPR Rabbit b 5 73 CYP3A4/NPR Rat b 5 70 Experiment 2 CYP3A4/NPR 38 4 CYP3A4/NPR b CYP3A4/NPR apo b CYP3A4/NPR cytochrome c 41 6 CYP3A4/NPR CYP1A NPR CYP1A2 0.1 In experiment 1, cytochrome b 5 (0.020 M) purified from E. coli membranes or from liver microsomes was added to CYP3A4/NPR membranes (0.010 M P-450 and M NPR). In experiment 2, other proteins (0.010 M) were added to CYP3A4/NPR membranes. Apo b 5 and CYP1A2 were prepared from rabbit liver b 5 and E. coli membranes expressing human CYP1A2, respectively. Results are presented as means S.D. of duplicate or triplicate determinations. affected by further addition of b 5 and/or NPR. Human liver microsomes containing 71% CYP3A4 (of total P-450) also were used. Based on CYP3A4 contents, the testosterone 6 -hydroxylation activity of this sample was 85 nmol/min/nmol CYP3A4. The molar ratio of CYP3A4/NPR/b 5 in this human liver microsomal preparation was 1:0.06:0.52, and testosterone 6 -hydroxylation was only minimally affected by the addition of recombinant b 5 or NPR. Nifedipine and midazolam oxidation activities of recombinant CYP3A4 systems and human liver microsomes also were determined (Table 5). In addition to a reconstituted system, the same enzyme sources as in Table 4 were used after addition of purified b 5 and NPR, with cholate added. Activities of nifedipine oxidation and midazolam 4- and 1 -hydroxylation of CYP3A4/NPR membranes plus b 5 and in the reconstituted system were similar to those of human liver microsomes ( 30, 10, and 20 min 1, respectively), based on CYP3A4 contents. Catalytic activities of microsomes of lymphoblastoid cells were lower, and nifedipine oxidation activities of a baculovirus sys-

4 1002 YAMAZAKI ET AL. TABLE 3 Cytochrome c reduction and CYP3A4-dependent testosterone 6 -hydroxylation by purified recombinant human and native rabbit NPR NPR a Cytochrome c Reduction b Molar Ratio of CYP3A4/NPR Testosterone 6 -Hydroxylation c mol/min/nmol NPR nmol/min/nmol CYP3A4 Human 3.2 1:2 16 1:4 41 1:6 70 1:8 79 Rabbit 3.1 1:2 76 a Human and rabbit NPR were purified from membranes of E. coli-expressing human NPR and from liver microsomes of phenobarbital-treated rabbits, respectively. b Rates of cytochrome c (50 M) reduction by NPR (5 nm) were recorded at 25 C in the presence of 0.1 mm NADPH. c Hydroxylation of testosterone (200 M) was determined at 37 C for 10 min in reconstitution systems containing purified recombinant CYP3A4 (0.010 M), NPR ( M), and human b 5 (0.010 M) with lipid mixture (20 g/ml) and cholate (0.25 mm) in the presence of an NADPH-generating system. Results are presented as means of duplicate determinations. tem that coexpressed b 5 and NPR were higher than those of human liver microsomes. Kinetic Analysis of Activity Catalyzed by CYP3A4/NPR Membranes Plus b 5 and Human Liver Microsomes. Because recombinant CYP3A4 (expressed in bacterial membranes using the bacterial bicistronic system) premixed at a molar ratio of 1:2:1 of CYP3A4 to human NPR to human b 5 appeared to be a suitable model for human liver microsomal CYP3A4 with regard to catalytic activities, kinetic parameters were compared with those of human liver microsomes. Testosterone 6 -hydroxylation was dependent on CYP3A4 concentration (Fig. 3); linearity of product formation was obtained in a narrow range ( M). Kinetic analysis for testosterone 6 hydroxylation over a substrate concentration range of 10 to 500 M yielded K m and V max values of M and nmol/ min/nmol CYP3A4 for the recombinant bacterial CYP3A4 system plus b 5 (1:2:1 molar ratio of CYP3A4/NPR/b 5 ) and M and nmol/min/nmol P-450 for human liver microsomes, respectively. Discussion A number of studies have shown that CYP3A4 is a major P-450 enzyme involved in the oxidation of many clinically used drugs in TABLE 4 Effects of exogenous NPR and b 5 on testosterone 6 -hydroxylation activities in CYP3A4/NPR membranes, microsomes containing recombinant CYP3A4/NPR, and human liver microsomes Enzymes Added NPR a Added b 5 b Testosterone 6 -hydroxylation nmol/min/nmol CYP3A4 E. coli membranes c Lymphoblastoid cell 14 microsomes d Baculosomes e Supersomes f Human liver 85 microsomes g 88 (HL-110) Testosterone (200 M) was incubated with CYP3A4 (0.010 M) for 10 min, and formed product was determined by HPLC. Results are presented as means of duplicate determinations. a Purified rabbit NPR (2-fold molar excess compared with CYP3A4) was added with 0.25 mm sodium cholate. b Purified human b 5 (2-fold molar excess compared with CYP3A4) was added. c E. coli membranes containing CYP3A4/NPR (1:1.1). d Microsomes of lymphoblastoid cells containing CYP3A4/NPR (1:1) (Gentest, lot 64). e Microsomes of insect cells with baculovirus system containing CYP3A4/NPR (1:4.6) (PanVera, lot 10345). f Microsomes of insect cells with baculovirus system containing CYP3A4/NPR/b 5 (1:12:16) (Gentest, lot 18). g The CYP3A4 content (71% of total P-450) in liver microsomes was determined immunochemically, and the molar ratio of CYP3A4/NPR/b 5 was 1:0.06:0.52. human liver microsomes (Guengerich, 1995; Wilkinson, 1996; Li et al., 1997). Prediction of microsomal oxidation of drugs in human livers has been studied recently using activities or kinetic parameters obtained from recombinant systems (Iwatsubo et al., 1997; Ito et al., 1998). A relative activity factor was proposed by Crespi (1995), and calculations have been reported with other factors (Kobayashi et al., FIG. 2.Concentration dependence of the effects of cholate and purified NPR on testosterone 6 -hydroxylation by CYP3A4/NPR membranes. A, cholate (0 1.0 mm) was added to CYP3A4/NPR membranes containing CYP3A4 (0.010 M) and human NPR (0.011 M), which were fortified further with exogenous rabbit NPR (0.010 M) with or without purified human b 5 (0.010 M). These components were mixed and allowed to stand 10 min at room temperature, followed by addition of other reaction components. Testosterone 6 -hydroxylation activities (200 M testosterone) were determined. B, exogenous rabbit NPR ( M) was added to CYP3A4/NPR membranes containing CYP3A4 (0.010 M) and human NPR (0.011 M), which were fortified with purified human b 5 (0.010 M) and/or cholate (0.25 mm). Testosterone 6 -hydroxylation activities were determined as described in A.

5 TESTOSTERONE, NIFEDIPINE, AND MIDAZOLAM OXIDATION BY CYP3A TABLE 5 Nifedipine and midazolam oxidation activities in a reconstitution system, CYP3A4/NPR membranes, microsomes containing recombinant CYP3A4/NPR, and human liver microsomes a CYP3A4 System b Nifedipine Oxidation 4- Hydroxylation Midazolam 1 - Hydroxylation nmol products/min/nmol CYP3A4 Reconstitution c E. coli membranes Lymphoblastoid cell microsomes Baculosomes Supersomes Human liver microsomes a Nifedipine (200 M) and midazolam (100 M) were incubated with CYP3A4 (0.010 M) for 5 min, and product formation was determined by HPLC. Data are the means of duplicate determinations. b The enzyme source was the same as in Table 4. Purified human b 5 (1:1 molar ratio compared with CYP3A4) and rabbit NADPH-P-450 reductase (2-fold molar excess compared with CYP3A4) were added with 0.25 mm sodium cholate. c Reconstitution systems containing purified CYP3A4 (0.010 M), rabbit NPR (0.020 M), and human b 5 (0.010 M) with lipid mixture (20 g/ml) and cholate (0.25 mm). FIG. 3.Effects of concentration of CYP3A4/NPR membranes premixed with b 5 on testosterone 6 -hydroxylation. Testosterone (200 M) was incubated with different concentrations of CYP3A4/ NPR membranes ( M CYP) premixed with human NPR and b 5 (1:2:1 molar ratio of CYP3A4/NPR/b 5 ). 1997; Nakajima et al., 1998; Venkatakrishnan et al., 1998). Omeprazole oxidation by human liver microsomes was predicted by using a combination of liver microsomal contents of CYP2C19 and CYP3A4 (immunochemically determined) and kinetic parameters obtained from experiments using recombinant CYP2C19 and CYP3A4 (Yamazaki et al., 1997b), using the methods outlined by Iwatsubo et al. (1997). In these studies, catalytic activities and kinetic parameters of marker drug oxidations catalyzed by recombinant P-450 enzymes are very important for prediction; however, different activities have been reported using several expression systems for CYP3A4 (Shaw et al., 1997; Yamazaki et al., 1997b). Drug oxidation activities of purified CYP3A4 have been studied extensively, and it has been shown that some CYP3A4 activities are dependent on b 5, specific lipid mixtures, cholate, and buffer and salt compositions (Yamazaki et al., 1996a; Shimada and Yamazaki, 1998). We have shown (using the purified recombinant CYP3A4 obtained from a monocistronic bacterial expression system) that a 1:2:1 molar ratio of CYP3A4/NPR/b 5 was suitable for reconstitution of drug oxidation (Yamazaki et al., 1996b). The present results indicate that a 1:2:1 molar ratio of CYP3A4/ NPR/b 5 gives apparently optimal activities for testosterone 6 -hydroxylation, nifedipine oxidation, and midazolam 4- and 1 -hydroxylations by recombinant CYP3A4 expressed in bacterial membranes using a bicistronic system. The molar ratio of the three proteins in membranes was the same as in a reconstituted system containing purified CYP3A4. Enhancing effects of exogenous b 5 were observed with either b 5 purified from human, rabbit, or rat liver microsomes, with recombinant human b 5 added in bacterial membranes or with apo b 5, devoid of heme. Effects of b 5 on CYP3A4 activities also were observed in microsomes from lymphoblastoid cells and insect cells (lacking endogenous b 5 ). Cholate (0.25 mm) was needed to enhance rates when purified NPR was added to CYP3A4 in bacterial membranes; however, cholate appeared not to be necessary when NPR was supplemented from bacterial membranes. Testosterone 6 -hydroxylation ( 80 min 1 ), nifedipine oxidation ( 30 min 1 ), and midazolam 4- and 1 -hydroxylation ( 10 and 20 min 1 ) activities were similar among human liver microsomes and/or baculovirus systems based on CYP3A4 contents. These results indicate that the bacterial CYP3A4/NPR membranes plus b 5 should be a simple and suitable model of drug oxidation study for microsomal CYP3A4-dependent reactions in human livers. NPR is essential to P-450-dependent drug oxidation, and many catalytic activities of CYP3A4 require b 5 for optimal rates. We have shown that b 5 can stimulate some CYP3A4-catalyzed oxidations by complexing with CYP3A4 in a synthetic phospholipid mixture, cholate, and MgCl 2 and enhancing its reduction by NPR without directly transferring electrons to P-450 (Yamazaki et al., 1996a). In the present study, purified b 5, membrane b 5 as well as apo b 5 enhanced the catalytic activities of CYP3A4 in bacterial membranes. Exogenous b 5 also was effective when added to microsomal CYP3A4 systems from lymphoblastoid and insect cells (lacking coexpressed b 5 ). This suggested that insertion of rabbit, rat, or human b 5 into the phospholipid bilayers is facile, and b 5 can make a suitable complex with CYP3A4 and NPR for efficient electron transfer. Similarly, the membrane-associated NPR was able to mix with membranes containing CYP3A4 and enhance catalytic activities; however, catalytic function of exogenous-purified NPR was dependent on the presence of added b 5 and cholate. Both cholate and b 5 may be necessary for insertion of purified NPR into phospholipid membranes or for complexation of purified NPR with CYP3A4. Cholate may not be an essential component for all of the activities catalyzed by CYP3A4 in reconstituted system; however, it sometimes has been helpful for reconstitution (Yamazaki et al., 1997a). Similar enhancing effects of cholate were observed at the same concentrations (0.01% w/v, or 0.25 mm) on catalytic activities of CYP1B1 in a reconstituted system (Shimada et al., 1998). In vitro assays are used to predict in vivo drug metabolism in humans. It has been reported that assay conditions, such as different buffers, salts, ionic strengths, detergent level, and components of NADPH-generating systems may affect the CYP3A4-mediated reactions (Yamazaki et al., 1997a; Mäenpää et al., 1998; Shimada and Yamazaki, 1998). Because effects of buffer and salt concentrations are likely to be more significant in reconstituted systems containing CYP3A4 than in human liver microsomes (Yamazaki et al., 1996b), we used 100 mm potassium phosphate buffer (ph 7.4) for drug metabolism reactions with CYP3A4/NPR membranes in this study. In conclusion, the present study suggested that CYP3A4 coexpressed with NPR in bacterial membranes supplemented with additional NPR plus b 5 is a very useful model for prediction of the rates

6 1004 YAMAZAKI ET AL. for microsomal CYP3A4-dependent drug oxidations in human livers. The ratio of NPR to CYP3A4 in human liver microsomes is low and very different from that found to give apparent maximal activities using the bacterial CYP3A4/NPR membranes. We reported previously that CYP3A4-dependent testosterone 6 -hydroxylation is stimulated by CYP1A2 in reconstitution systems (Yamazaki et al., 1997a). In this study, CYP1A2 also enhanced catalytic activities of CYP3A4/ NPR membranes. These findings indicate the potential for one P-450 enzyme to influence the catalytic characteristics of another P-450 enzyme when a low amount of NPR is present in human liver microsomes. Further studies are necessary for optimization of recombinant P-450 enzyme systems for use as human liver models. References Brian WR, Sari MA, Iwasaki M, Shimada T, Kaminsky LS and Guengerich FP (1990) Catalytic activities of human liver cytochrome P-450IIIA4 expressed in Saccharomyces cerevisiae. Biochemistry 29: Buters J, Korzekwa KR, Kunze KL, Omata Y, Hardwick JP and Gonzalez FJ (1994) cdnadirected expression of human cytochrome P450 CYP3A4 using baculovirus. Drug Metab Dispos 22: Crespi CL (1995) Xenobiotic-metabolizing human cells as tools for pharmacological and toxicological research. Adv Drug Res 26: Dong M-S, Yamazaki H, Guo Z and Guengerich FP (1996) Recombinant human cytochrome P450 1A2 and N-terminal-truncated form: Construction, purification, aggregation properties, and interactions with flavodoxin, ferredoxin, and NADPH-cytochrome P450 reductase. Arch Biochem Biophys 327: Gillam E, Baba T, Kim B-R, Ohmori S and Guengerich FP (1993) Expression of modified human cytochrome P450 3A4 in Escherichia coli and purification and reconstitution of the enzyme. Arch Biochem Biophys 305: Gonzalez FJ, Crespi CL and Gelboin HV (1991) cdna-expressed human cytochrome P450s: A new age of molecular toxicology and human risk assessment. Mutat Res 247: Gonzalez FJ and Gelboin HV (1994) Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins. Drug Metab Rev 26: Guengerich FP (1994) Analysis and characterization of enzymes, in Principles and Methods of Toxicology (Hayes AW ed) pp , Raven Press, New York. Guengerich FP (1995) Human cytochrome P450 enzymes, in Cytochrome P450 (Oritiz de Montellano PR ed) pp , Plenum Press, New York. Guengerich FP, Martin MV, Guo Z and Chun Y-J (1996) Purification of functional recombinant P450s from bacteria. Methods Enzymol 272: Guengerich FP and Shimada T (1991) Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem Res Toxicol 4: Guengerich FP, Wang P and Davidson NK (1982) Estimation of isozymes of microsomal cytochrome P-450 in rats, rabbits, and humans using immunochemical staining coupled with sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Biochemistry 21: Guengerich FP, Wang P and Mason PS (1981) Immunological comparison of rat, rabbit, and human liver NADPH-cytochrome P-450 reductase. Biochemistry 20: Imaoka S, Yamada T, Hiroi T, Hayashi K, Sakai T, Yabusaki Y and Funae Y (1996) Multiple forms of human P450 expressed in Saccharomyces cerevisiae. Systematic characterization and comparison with those of the rat. Biochem Pharmacol 51: Inoue K, Yamazaki H, Imiya K, Akasaka S, Guengerich FP and Shimada T (1997) Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S- mephenytoin 4 -hydroxylation activities in livers of Japanese and Caucasian populations. Pharmacogenetics 7: Ito K, Iwatsubo T, Kanamitsu S, Nakajima Y and Sugiyama Y (1998) Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. Annu Rev Pharmacol Toxicol 38: Iwatsubo T, Hirota N, Ooie T, Suzuki H, Shimada N, Chiba K, Ishizaki T, Green CE, Tyson CA and Sugiyama Y (1997) Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol Ther 73: Kobayashi K, Chiba K, Yagi T, Shimada N, Taniguchi T, Horie T, Tani M, Yamamoto T, Ishizaki T and Kuroiwa Y (1997) Identification of cytochrome P450 isoforms involved in citalopram N-demethylation by human liver microsomes. J Pharmacol Exp Ther 280: Kronbach T, Mathys D, Umeno M, Gonzalez FJ and Meyer UA (1989) Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 36: Lee CA, Kadwell SH, Kost TA and Serbjit-Singh CJ (1995) CYP3A4 expressed by insect cells infected with a recombinant baculovirus containing both CYP3A4 and human NADPHcytochrome P450 reductase is catalytically similar to human liver microsomal CYP3A4. Arch Biochem Biophys 319: Li AP, Maurel P, Gomez-Lechon MJ, Cheng LC and Jurima-Romet M (1997) Preclinical evaluation of drug-drug interaction potential: Present status of the application of primary human hepatocytes in the evaluation of cytochrome P450 induction. Chem Biol Interact 107:5 16. Lowry OH, Rosebrough NJ, Farr AL and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193: Mäenpää J, Hall SD, Ring BJ, Strom SC and Wrighton SA (1998) Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: The effect of assay conditions and regioselective stimulation by -naphthoflavone, terfenadine and testosterone. Pharmacogenetics 8: Nakajima M, Kobayashi K, Shimada N, Tokudome S, Yamamoto T and Kuroiwa Y (1998) Involvement of CYP1A2 in mexiletine metabolism. Br J Clin Pharmacol 46: Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, Gunsalus IC and Nebert DW (1996) P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6:1 42. Omura T and Sato R (1964) The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239: Parikh A, Gillam EMJ and Guengerich FP (1997) Bacterial catalysis of reactions important in mammalian drug and xenobiotic metabolism: Functional co-expression of six human microsomal cytochrome P450 enzymes with NADPH-cytochrome P450 reductase in Escherichia coli. Nat Biotechnol 15: Renaud JP, Peyronneau MA, Urban P, Truan G, Cullin C, Pompon D, Beaune P and Mansuy D (1993) Recombinant yeast in drug metabolism. Toxicology 82: Shaw PM, Hosea NA, Thompson DV, Lenius JM and Guengerich FP (1997) Reconstitution premixes for assays using purified recombinant human cytochrome P450, NADPHcytochrome P450 reductase, and cytochrome b 5. Arch Biochem Biophys 348: Shimada T, Misono KS and Guengerich FP (1986) Human liver microsomal cytochrome P-450 mephenytoin 4-hydroxylase, a prototype of genetic polymorphism in oxidative drug metabolism. Purification and characterization of two similar forms involved in the reaction. J Biol Chem 261: Shimada T, Wunsch RM, Hanna IH, Sutter TR, Guengerich FP and Gillam EMJ (1998) Recombinant human cytochrome P450 1B1 expression in Escherichia coli. Arch Biochem Biophys 357: Shimada T and Yamazaki H (1998) Cytochrome P450 reconstitution systems, in Methods in Molecular Biology (Phillips IR and Shephard EA eds) pp 85 93, Humana Press, Totowa, NJ. Shimada T, Yamazaki H, Mimura M, Inui Y and Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270: Strittmatter P, Fleming P, Connors M and Corcoran D (1978) Purification of cytochrome b 5. Methods Enzymol 52: Venkatakrishnan K, von Moltke LL and Greenblatt DJ (1998) Relative quantities of catalytically active CYP 2C9 and 2C19 in human liver microsomes: Application of the relative activity factor approach. J Pharm Sci 87: Wilkinson GR (1996) Cytochrome P4503A (CYP3A) metabolism: Prediction of in vivo activity in humans. J Pharmacokin Biopharm 24: Williams CH Jr and Kamin H (1962) Microsomal triphosphopyridine nucleotide-cytochrome c reductase of liver. J Biol Chem 237: Wrighton SA and Stevens JC (1992) The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 22:1 21. Yamazaki H, Gillam EMJ, Dong M-S, Johnson WW, Guengerich FP and Shimada T (1997a) Reconstitution of recombinant cytochrome P450 2C10 (2C9) and comparison with cytochrome P450 3A4 and other forms: Effects of cytochrome P450 P450 and cytochrome P450-b 5 interactions. Arch Biochem Biophys 342: Yamazaki H, Inoue K, Shaw PM, Checovich WJ, Guengerich FP and Shimada T (1997b) Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: Effects of contents of these two forms in individual human samples. J Pharmacol Exp Ther 283: Yamazaki H, Johnson WW, Ueng Y-F, Shimada T and Guengerich FP (1996a) Lack of electron transfer from cytochrome b 5 in stimulation of catalytic activities of cytochrome P450 3A4. Characterization of a reconstituted cytochrome P450 3A4/NADPH-cytochrome P450 reductase system and studies with apo cytochrome b 5. J Biol Chem 271: Yamazaki H, Nakano M, Imai Y, Ueng Y-F, Guengerich FP and Shimada T (1996b) Roles of cytochrome b 5 in the oxidation of testosterone and nifedipine by recombinant cytochrome P450 3A4 and by human liver microsomes. Arch Biochem Biophys 325: Yasukochi Y and Masters BSS (1976) Some properties of a detergent-solubilized NADPHcytochrome c (cytochrome P-450) reductase purified by biospecific affinity chromatography. J Biol Chem 251:

HIROSHI YAMAZAKI, KIYOSHI INOUE, PETER M. SHAW, WILLIAM J. CHECOVICH, F. PETER GUENGERICH and TSUTOMU SHIMADA

HIROSHI YAMAZAKI, KIYOSHI INOUE, PETER M. SHAW, WILLIAM J. CHECOVICH, F. PETER GUENGERICH and TSUTOMU SHIMADA 0022-3565/97/2832-0434$03.00/0 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Vol. 283, No. 2 Copyright 1997 by The American Society for Pharmacology and Experimental Therapeutics Printed in

More information

INVOLVEMENT OF CYP2E1 AS A LOW-AFFINITY ENZYME IN PHENACETIN O-DEETHYLATION IN HUMAN LIVER MICROSOMES

INVOLVEMENT OF CYP2E1 AS A LOW-AFFINITY ENZYME IN PHENACETIN O-DEETHYLATION IN HUMAN LIVER MICROSOMES 0090-9556/99/2708-0860 865$02.00/0 DRUG METABOLISM AND DISPOSITION Vol. 27, No. 8 Copyright 1999 by The American Society for Pharmacology and Experimental Therapeutics Printed in U.S.A. INVOLVEMENT OF

More information

METABOLISM OF ( )- AND ( )-LIMONENES TO RESPECTIVE CARVEOLS AND PERILLYL ALCOHOLS BY CYP2C9 AND CYP2C19 IN HUMAN LIVER MICROSOMES

METABOLISM OF ( )- AND ( )-LIMONENES TO RESPECTIVE CARVEOLS AND PERILLYL ALCOHOLS BY CYP2C9 AND CYP2C19 IN HUMAN LIVER MICROSOMES 0090-9556/02/3005-602 607$7.00 DRUG METABOLISM AND DISPOSITION Vol. 30, No. 5 Copyright 2002 by The American Society for Pharmacology and Experimental Therapeutics 641/981193 DMD 30:602 607, 2002 Printed

More information

BIOCHEMISTRY and MOLECULAR BIOLOGY INTERNATIONAL DIFFERENTIAL INHIBITION OF AFLATOXIN B1 OXIDATION BY GESTODENE ACTION ON HUMAN LIVER MICROSOMES

BIOCHEMISTRY and MOLECULAR BIOLOGY INTERNATIONAL DIFFERENTIAL INHIBITION OF AFLATOXIN B1 OXIDATION BY GESTODENE ACTION ON HUMAN LIVER MICROSOMES Vol. 43, No. 4, November 1997 Pages 839-846 DIFFERENTIAL INHIBITION OF AFLATOXIN B1 OXIDATION BY GESTODENE ACTION ON HUMAN LIVER MICROSOMES Bok Ryang Kim,* Hyun Sook Oh,** and Dong-Hyun Kim ~t'l *Department

More information

ROLES OF HUMAN CYP2A6 AND 2B6 AND RAT CYP2C11 AND 2B1 IN THE 10-HYDROXYLATION OF ( )-VERBENONE BY LIVER MICROSOMES

ROLES OF HUMAN CYP2A6 AND 2B6 AND RAT CYP2C11 AND 2B1 IN THE 10-HYDROXYLATION OF ( )-VERBENONE BY LIVER MICROSOMES 0090-9556/03/3108-1049 1053$7.00 DRUG METABOLISM AND DISPOSITION Vol. 31, No. 8 Copyright 2003 by The American Society for Pharmacology and Experimental Therapeutics 1076/1078953 DMD 31:1049 1053, 2003

More information

Effective NADH-Dependent Oxidation of 7b -Hydroxy-D 8 - tetrahydrocannabinol to the Corresponding Ketone by Japanese Monkey Hepatic Microsomes

Effective NADH-Dependent Oxidation of 7b -Hydroxy-D 8 - tetrahydrocannabinol to the Corresponding Ketone by Japanese Monkey Hepatic Microsomes 646 Biol. Pharm. Bull. 28(4) 646 651 (2005) Vol. 28, No. 4 Effective NADH-Dependent Oxidation of 7b -Hydroxy-D 8 - tetrahydrocannabinol to the Corresponding Ketone by Japanese Monkey Hepatic Microsomes

More information

Rat cytochrome P450 2C11 in liver microsomes involved in oxidation of. anesthetic agent propofol and deactivated by prior treatment with

Rat cytochrome P450 2C11 in liver microsomes involved in oxidation of. anesthetic agent propofol and deactivated by prior treatment with DMD Fast This article Forward. has not been Published copyedited on and August formatted. 8, The 2006 final version as doi:10.1124/dmd.106.011627 may differ from this version. Rat cytochrome P450 2C11

More information

CATALYTIC SPECIFICITY OF CYP2D ISOFORMS IN RAT AND HUMAN

CATALYTIC SPECIFICITY OF CYP2D ISOFORMS IN RAT AND HUMAN 0090-9556/02/3009-970 976$7.00 DRUG METABOLISM AND DISPOSITION Vol. 30, No. 9 Copyright 2002 by The American Society for Pharmacology and Experimental Therapeutics 696/1004051 DMD 30:970 976, 2002 Printed

More information

FORMATION OF A DIHYDROXY METABOLITE OF PHENYTOIN IN HUMAN LIVER MICROSOMES/CYTOSOL: ROLES OF CYTOCHROMES P450 2C9, 2C19, AND 3A4

FORMATION OF A DIHYDROXY METABOLITE OF PHENYTOIN IN HUMAN LIVER MICROSOMES/CYTOSOL: ROLES OF CYTOCHROMES P450 2C9, 2C19, AND 3A4 0090-9556/00/2811-1361 1368$03.00/0 DRUG METABOLISM AND DISPOSITION Vol. 28, No. 11 Copyright 2000 by The American Society for Pharmacology and Experimental Therapeutics 63/859475 DMD 28:1361 1368, 2000

More information

Identification of Cytochrome P450 Isoforms Involved in Citalopram N-Demethylation by Human Liver Microsomes 1

Identification of Cytochrome P450 Isoforms Involved in Citalopram N-Demethylation by Human Liver Microsomes 1 0022-3565/97/2802-0927$03.00/0 THE JOURNAL OF PHARMACOLOGY A EXPERIMENTAL THERAPEUTICS Vol. 280, No. 2 Copyright 1997 by The American Society for Pharmacology and Experimental Therapeutics Printed in U.S.A.

More information

Hepatic mitochondrial cytochrome P-450: Isolation

Hepatic mitochondrial cytochrome P-450: Isolation Proc. Nati. Acad. Sci. USA Vol. 74, No. 12, pp. 5477-5481, December 1977 Biochemistry Hepatic mitochondrial cytochrome P-45: Isolation and functional characterization (heme protein/liver mitochondria/bile

More information

Metabolism and metabolic inhibition of cilnidipine in human liver microsomes 1

Metabolism and metabolic inhibition of cilnidipine in human liver microsomes 1 263 2003, Acta Pharmacologica Sinica Chinese Pharmacological Society Shanghai Institute of Materia Medica Chinese Academy of Sciences http://www.chinaphar.com Metabolism and metabolic inhibition of cilnidipine

More information

XTreme 200 Human Liver Microsomes Lot No Human Liver Microsomes Pool of 200 (100 Male and 100 Female) Suspension medium: 250 mm sucrose

XTreme 200 Human Liver Microsomes Lot No Human Liver Microsomes Pool of 200 (100 Male and 100 Female) Suspension medium: 250 mm sucrose XTreme 200 Human Liver Microsomes Lot No. 1710084 Human Liver Microsomes Pool of 200 (100 Male and 100 Female) Suspension medium: 250 mm sucrose H2610 0.5 ml at 20 mg/ml H2620 1.0 ml at 20 mg/ml H2630

More information

Arena Pharmaceuticals, Inc., Department of Drug Metabolism and Pharmacokinetics, San Diego, California

Arena Pharmaceuticals, Inc., Department of Drug Metabolism and Pharmacokinetics, San Diego, California 1521-009X/12/4004-761 771$25.00 DRUG METABOLISM AND DISPOSITION Vol. 40, No. 4 Copyright 2012 by The American Society for Pharmacology and Experimental Therapeutics 43414/3759637 DMD 40:761 771, 2012 Identification

More information

Experimental approaches to evaluate activities of cytochromes P450 3A

Experimental approaches to evaluate activities of cytochromes P450 3A Interdisc Toxicol. 28; Vol. 1(2): 155 159. doi: 1.2478/v112-1-32- Published online in: www.intertox.sav.sk & www.versita.com/science/medicine/it/ Copyright 21 Slovak Toxicology Society SETOX This is an

More information

Stereoselective Metabolism of Bufuralol Racemate and Enantiomers in Human Liver Microsomes

Stereoselective Metabolism of Bufuralol Racemate and Enantiomers in Human Liver Microsomes 0022-3565/02/3031-172 178$7.00 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Vol. 303, No. 1 Copyright 2002 by The American Society for Pharmacology and Experimental Therapeutics 36533/1006673

More information

THE ALKALOID RUTAECARPINE IS A SELECTIVE INHIBITOR OF CYTOCHROME P450 1A IN MOUSE AND HUMAN LIVER MICROSOMES

THE ALKALOID RUTAECARPINE IS A SELECTIVE INHIBITOR OF CYTOCHROME P450 1A IN MOUSE AND HUMAN LIVER MICROSOMES 0090-9556/02/3003-349 353$3.00 DRUG METABOLISM AND DISPOSITION Vol. 30, No. 3 Copyright 2002 by The American Society for Pharmacology and Experimental Therapeutics 513/966050 DMD 30:349 353, 2002 Printed

More information

Interactions between CYP2C9 and CYP2C19 in Reconstituted Binary. Systems Influence their Catalytic Activity: Possible rationale for the inability

Interactions between CYP2C9 and CYP2C19 in Reconstituted Binary. Systems Influence their Catalytic Activity: Possible rationale for the inability DMD Fast This Forward. article has not Published been copyedited on and October formatted. 14, The 2004 final version as doi:10.1124/dmd.104.001578 may differ from this version. DMD #1578R Interactions

More information

KARTHIK VENKATAKRISHNAN, LISA L. VON MOLTKE, and DAVID J. GREENBLATT

KARTHIK VENKATAKRISHNAN, LISA L. VON MOLTKE, and DAVID J. GREENBLATT 0022-3565/01/2971-326 337$3.00 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Vol. 297, No. 1 Copyright 2001 by The American Society for Pharmacology and Experimental Therapeutics 3324/893791

More information

CYP2C19 PARTICIPATES IN TOLBUTAMIDE HYDROXYLATION BY HUMAN LIVER MICROSOMES

CYP2C19 PARTICIPATES IN TOLBUTAMIDE HYDROXYLATION BY HUMAN LIVER MICROSOMES 0090-9556/00/2803-0354 359$02.00/0 DRUG METABOLISM AND DISPOSITION Vol. 28, No. 3 Copyright 2000 by The American Society for Pharmacology and Experimental Therapeutics Printed in U.S.A. CYP2C19 PARTICIPATES

More information

P450I I E 1 Gene : Dra I. Human Cytochrome Polymorphism and

P450I I E 1 Gene : Dra I. Human Cytochrome Polymorphism and Tohoku J. Exp. Med., 1992, 168, 113-117 Human Cytochrome Polymorphism and P450I I E 1 Gene : Dra I Susceptibility to Cancer FUMIYUKI VEMATSUHIDEAKI KIKUCHI*, MASAKICHI MOTOMIYA j', TATSUYA ABE j', CHIKASHI

More information

DRUG INTERACTION BETWEEN SIMVASTATIN AND ITRACONAZOLE IN MALE AND FEMALE RATS

DRUG INTERACTION BETWEEN SIMVASTATIN AND ITRACONAZOLE IN MALE AND FEMALE RATS 0090-9556/01/2907-1068 1072$3.00 DRUG METABOLISM AND DISPOSITION Vol. 29, No. 7 Copyright 2001 by The American Society for Pharmacology and Experimental Therapeutics 331/915884 DMD 29:1068 1072, 2001 Printed

More information

AND LIVER MICROSOMAL P-450 PROFILES

AND LIVER MICROSOMAL P-450 PROFILES 0090-9556/99/2706-0655 666$02.00/0 DRUG METABOLISM AND DISPOSITION Vol. 27, No. 6 Copyright 1999 by The American Society for Pharmacology and Experimental Therapeutics Printed in U.S.A. DEVELOPMENT OF

More information

Received May 30, 2007; accepted August 15, 2007

Received May 30, 2007; accepted August 15, 2007 0090-9556/07/3511-1990 1995$20.00 DRUG METABOLISM AND DISPOSITION Vol. 35, No. 11 Copyright 2007 by The American Society for Pharmacology and Experimental Therapeutics 16816/3267964 DMD 35:1990 1995, 2007

More information

SUPPLEMENTARY MATERIAL

SUPPLEMENTARY MATERIAL SUPPLEMENTARY MATERIAL Purification and biochemical properties of SDS-stable low molecular weight alkaline serine protease from Citrullus Colocynthis Muhammad Bashir Khan, 1,3 Hidayatullah khan, 2 Muhammad

More information

STUDIES ON ASPIRIN ESTERASE OF HUMAN SERUM. Masako MORIKAWA, Michiko INOUE, Minoru TSUBOI. and Mamoru SUGIURA*

STUDIES ON ASPIRIN ESTERASE OF HUMAN SERUM. Masako MORIKAWA, Michiko INOUE, Minoru TSUBOI. and Mamoru SUGIURA* STUDIES ON ASPIRIN ESTERASE OF HUMAN SERUM Masako MORIKAWA, Michiko INOUE, Minoru TSUBOI and Mamoru SUGIURA* Department of Pharmacology, Tokyo College of Pharmacy, Horinouchi, Hachioji-shi, Tokyo 192-03,

More information

Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes

Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes Differential selectivity of cytochrome P4 inhibitors against probe substrates in human and rat liver microsomes Victoria A. Eagling, John F. Tjia & David J. Back Department of Pharmacology & Therapeutics,

More information

GLYCATION OF PROTEINS IN ESCHERICHIA COLI: EFFECT OF NUTRIENT BROTH INGREDIENTS ON GLYCATION

GLYCATION OF PROTEINS IN ESCHERICHIA COLI: EFFECT OF NUTRIENT BROTH INGREDIENTS ON GLYCATION Industry GLYCATION OF PROTEINS IN ESCHERICHIA COLI: EFFECT OF NUTRIENT BROTH INGREDIENTS ON GLYCATION R. Dimitrova, R. Mironova, I. Ivanov Institute of Molecular biology, Bulgarian Academy of Sciences

More information

TSUTOMU SHIMADA, YOSHIMITSU ODA, ELIZABETH M. J. GILLAM, F. PETER GUENGERICH, AND KIYOSHI INOUE

TSUTOMU SHIMADA, YOSHIMITSU ODA, ELIZABETH M. J. GILLAM, F. PETER GUENGERICH, AND KIYOSHI INOUE 0090-9556/01/2909-1176 1182$3.00 DRUG METABOLISM AND DISPOSITION Vol. 29, No. 9 Copyright 2001 by The American Society for Pharmacology and Experimental Therapeutics 403/923026 DMD 29:1176 1182, 2001 Printed

More information

CYP2A6 AND CYP2B6 ARE INVOLVED IN NORNICOTINE FORMATION FROM NICOTINE IN HUMANS: INTERINDIVIDUAL DIFFERENCES IN THESE CONTRIBUTIONS

CYP2A6 AND CYP2B6 ARE INVOLVED IN NORNICOTINE FORMATION FROM NICOTINE IN HUMANS: INTERINDIVIDUAL DIFFERENCES IN THESE CONTRIBUTIONS 0090-9556/05/3312-1811 1818$20.00 DRUG METABOLISM AND DISPOSITION Vol. 33, No. 12 Copyright 2005 by The American Society for Pharmacology and Experimental Therapeutics 6254/3063240 DMD 33:1811 1818, 2005

More information

UTILITY OF RECOMBINANT ENZYME KINETICS IN PREDICTION OF HUMAN CLEARANCE: IMPACT OF VARIABILITY, CYP3A5, AND CYP2C19 ON CYP3A4 PROBE SUBSTRATES

UTILITY OF RECOMBINANT ENZYME KINETICS IN PREDICTION OF HUMAN CLEARANCE: IMPACT OF VARIABILITY, CYP3A5, AND CYP2C19 ON CYP3A4 PROBE SUBSTRATES 0090-9556/04/3212-1411 1420$20.00 DRUG METABOLISM AND DISPOSITION Vol. 32, No. 12 Copyright 2004 by The American Society for Pharmacology and Experimental Therapeutics 844/1183369 DMD 32:1411 1420, 2004

More information

Role of NADPH-cytochrome P450 reductase and cytochrome b 5 / NADH b 5 reductase in. variability of CYP3A activity in human liver microsomes

Role of NADPH-cytochrome P450 reductase and cytochrome b 5 / NADH b 5 reductase in. variability of CYP3A activity in human liver microsomes DMD Fast This article Forward. has not Published been copyedited on and October formatted. The 6, 2008 final version as doi:10.1124/dmd.108.023424 may differ from this version. Role of NADPH-cytochrome

More information

PREDICTION OF IN VIVO DRUG-DRUG INTERACTIONS BETWEEN TOLBUTAMIDE AND VARIOUS SULFONAMIDES IN HUMANS BASED ON IN VITRO EXPERIMENTS

PREDICTION OF IN VIVO DRUG-DRUG INTERACTIONS BETWEEN TOLBUTAMIDE AND VARIOUS SULFONAMIDES IN HUMANS BASED ON IN VITRO EXPERIMENTS 0090-9556/00/2804-0475 481$02.00/0 DRUG METABOLISM AND DISPOSITION Vol. 28, No. 4 Copyright 2000 by The American Society for Pharmacology and Experimental Therapeutics Printed in U.S.A. PREDICTION OF IN

More information

CYP2A6 and CYP2B6 are involved in nornicotine formation from nicotine in humans: Interindividual differences in these contributions

CYP2A6 and CYP2B6 are involved in nornicotine formation from nicotine in humans: Interindividual differences in these contributions DMD Fast This article Forward. has not Published been copyedited on and August formatted. 31, The 2005 final version as doi:10.1124/dmd.105.006254 may differ from this version. CYP2A6 and CYP2B6 are involved

More information

SUPPORTING INFORMATION

SUPPORTING INFORMATION SUPPORTING INFORMATION Reduction of Aromatic and Heterocyclic Aromatic N-Hydroxylamines by Human Cytochrome P450 2S1 Wang, K., and Guengerich, F. P. (2013) Chem. Res. Toxicol. 26, 000-000 Figure S1. HPLC

More information

Metabolic differences in colon mucosal cells

Metabolic differences in colon mucosal cells Metabolic differences in colon mucosal cells Ross A. McKinnon a Wendy M. Burgess a, Frank J. Gonzalez b and Michael E. McManus c a Department of Clinical Pharmacology, Flinders University, South Australia

More information

Scholars Research Library. Purification and characterization of neutral protease enzyme from Bacillus Subtilis

Scholars Research Library. Purification and characterization of neutral protease enzyme from Bacillus Subtilis Journal of Microbiology and Biotechnology Research Scholars Research Library J. Microbiol. Biotech. Res., 2012, 2 (4):612-618 (http://scholarsresearchlibrary.com/archive.html) Purification and characterization

More information

Large interindividual variability in the in vitro formation of tamoxifen metabolites related to the development of genotoxicity

Large interindividual variability in the in vitro formation of tamoxifen metabolites related to the development of genotoxicity et al. DOI:1.146/j.1365-2125.3.197.x British Journal of Clinical Pharmacology Large interindividual variability in the in vitro formation of tamoxifen metabolites related to the development of genotoxicity

More information

Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine, in

Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine, in DMD Fast This article Forward. has not been Published copyedited on and June formatted. 11, The 2012 final version as doi:10.1124/dmd.112.045237 may differ from this version. Metabolism of the active metabolite

More information

Characterization of the DNA-mediated Oxidation of Dps, a Bacterial Ferritin

Characterization of the DNA-mediated Oxidation of Dps, a Bacterial Ferritin SUPPORTING INFORMATION Characterization of the DNA-mediated Oxidation of Dps, a Bacterial Ferritin Anna R. Arnold, Andy Zhou, and Jacqueline K. Barton Division of Chemistry and Chemical Engineering, California

More information

Work-flow: protein sample preparation Precipitation methods Removal of interfering substances Specific examples:

Work-flow: protein sample preparation Precipitation methods Removal of interfering substances Specific examples: Dr. Sanjeeva Srivastava IIT Bombay Work-flow: protein sample preparation Precipitation methods Removal of interfering substances Specific examples: Sample preparation for serum proteome analysis Sample

More information

Supporting Information for:

Supporting Information for: Supporting Information for: Methylerythritol Cyclodiphosphate (MEcPP) in Deoxyxylulose Phosphate Pathway: Synthesis from an Epoxide and Mechanisms Youli Xiao, a Rodney L. Nyland II, b Caren L. Freel Meyers

More information

EVALUATION OF CYTOCHROME P450 PROBE SUBSTRATES COMMONLY USED BY THE PHARMACEUTICAL INDUSTRY TO STUDY IN VITRO DRUG INTERACTIONS

EVALUATION OF CYTOCHROME P450 PROBE SUBSTRATES COMMONLY USED BY THE PHARMACEUTICAL INDUSTRY TO STUDY IN VITRO DRUG INTERACTIONS 0090-9556/02/3012-1311 1319 DRUG METABOLISM AND DISPOSITION Vol. 30, No. 12 U.S. Government work not protected by U.S. copyright 548/1028208 DMD 30:1311 1319, 2002 Printed in U.S.A. EVALUATION OF CYTOCHROME

More information

Glutathione Peroxidase Assay Kit

Glutathione Peroxidase Assay Kit Glutathione Peroxidase Assay Kit Catalog Number KA0882 100 assays Version: 04 Intended for research use only www.abnova.com Table of Contents Introduction... 3 Background... 3 General Information... 4

More information

IN VITRO BIOTRANSFORMATION OF SILDENAFIL (VIAGRA): IDENTIFICATION OF HUMAN CYTOCHROMES AND POTENTIAL DRUG INTERACTIONS

IN VITRO BIOTRANSFORMATION OF SILDENAFIL (VIAGRA): IDENTIFICATION OF HUMAN CYTOCHROMES AND POTENTIAL DRUG INTERACTIONS 0090-9556/00/2804-0392 397$02.00/0 DRUG METABOLISM AND DISPOSITION Vol. 28, No. 4 Copyright 2000 by The American Society for Pharmacology and Experimental Therapeutics Printed in U.S.A. IN VITRO BIOTRANSFORMATION

More information

MECHANISM-BASED INACTIVATION OF CYP2C11 BY DICLOFENAC

MECHANISM-BASED INACTIVATION OF CYP2C11 BY DICLOFENAC 0090-9556/01/2909-1190 1195$3.00 DRUG METABOLISM AND DISPOSITION Vol. 29, No. 9 Copyright 2001 by The American Society for Pharmacology and Experimental Therapeutics 400/923028 DMD 29:1190 1195, 2001 Printed

More information

Stable isotope labeled Media products

Stable isotope labeled Media products www.isotope.com RESEARCH PRODUCTS Stable isotope labeled Media products Bacterial Cell Growth Insect Cell Growth Mammalian Cell Growth Yeast Cell Growth Minimal Media for Bacterial Cell Growth Spectra

More information

Pilot experiments to investigate the glucuronidation of axitinib with human liver microsomes.

Pilot experiments to investigate the glucuronidation of axitinib with human liver microsomes. Zientek MA, Goosen TC, Tseng E, Lin J, Bauman JN, Walker GS, Kang P, Jiang Y, Freiwald S, Neul D and Smith BJ. In Vitro Kinetic Characterization of Axitinib Metabolism. Drug Metab Dispos. Supplemental

More information

BIOCHEMISTRY and MOLECULAR BIOLOGY INTERNATIONAL Pages 48]-486

BIOCHEMISTRY and MOLECULAR BIOLOGY INTERNATIONAL Pages 48]-486 Vol. 41, No. 3, March 1997 BIOCHEMISTRY and MOLECULAR BIOLOGY INTERNATIONAL Pages 48]-486 INACTIVATION OF ACONITASE IN YEAST EXPOSED TO OXIDATIVE STRESS Keiko Murakami and Masataka Yoshino* Department

More information

Stable Isotope Labeled Media Products

Stable Isotope Labeled Media Products www.iso ope.com Cambridge Iso ope Labora ories, Inc. www.iso ope.com RESEARCH PRODUC S Stable Isotope Labeled Media Products Cambridge Iso ope Labora ories, Inc. Minimal Media for Bacterial Cell Growth

More information

Human cytochrome P450 mono-oxygenase system is suppressed by propofol

Human cytochrome P450 mono-oxygenase system is suppressed by propofol British Journal of Anaesthesia 1995; 74: 558-562 Human cytochrome P450 mono-oxygenase system is suppressed by propofol T. L. CHEN, T. H. UENG, S. H. CHEN, P. H. LEE, S. Z. FAN AND C. C. LIU Summary We

More information

Optimal Dose of Omeprazole for CYP2C19 Extensive Metabolizers in Anti-Helicobacter pylori Therapy: Pharmacokinetic Considerations

Optimal Dose of Omeprazole for CYP2C19 Extensive Metabolizers in Anti-Helicobacter pylori Therapy: Pharmacokinetic Considerations July 2002 Notes Biol. Pharm. Bull. 25(7) 923 927 (2002) 923 Optimal Dose of Omeprazole for CYP2C19 Extensive Metabolizers in Anti-Helicobacter pylori Therapy: Pharmacokinetic Considerations Tomoko KITA,

More information

Structural Biology of Membrane Proteins: Are There Any Rules? D.C. Rees Caltech/HHMI NIH Roadmap Meeting

Structural Biology of Membrane Proteins: Are There Any Rules? D.C. Rees Caltech/HHMI NIH Roadmap Meeting Structural Biology of Membrane Proteins: Are There Any Rules? D.C. Rees Caltech/HHMI NIH Roadmap Meeting Are there any rules? no magic bullets (shots on goal) proteins that are polydisperse crystallize

More information

CYTOCHROME P-450 3A4 AND 2C8 ARE INVOLVED IN ZOPICLONE METABOLISM

CYTOCHROME P-450 3A4 AND 2C8 ARE INVOLVED IN ZOPICLONE METABOLISM 0090-9556/99/2709-1068 1073$02.00/0 DRUG METABOLISM AND DISPOSITION Vol. 27, No. 9 Copyright 1999 by The American Society for Pharmacology and Experimental Therapeutics Printed in U.S.A. CYTOCHROME P-450

More information

Stable Isotope Labeled Media Products

Stable Isotope Labeled Media Products Cambridge Isotope Laboratories, Inc. www.isotope.com RESEARCH PRODUCTS Stable Isotope Labeled Media Products Bacterial Cell Growth Insect Cell Growth Mammalian Cell Growth Yeast Cell Growth Cambridge Isotope

More information

FUNCTIONAL CHARACTERIZATION OF CYTOCHROME P450 2B6 ALLELIC VARIANTS

FUNCTIONAL CHARACTERIZATION OF CYTOCHROME P450 2B6 ALLELIC VARIANTS 0090-9556/03/3104-398 403$7.00 DRUG METABOLISM AND DISPOSITION Vol. 31, No. 4 Copyright 2003 by The American Society for Pharmacology and Experimental Therapeutics 973/1050100 DMD 31:398 403, 2003 Printed

More information

EFFECT OF MULTIPLE DOSING OF KETOCONAZOLE ON PHARMACOKINETICS OF MIDAZOLAM, A CYTOCHROME P-450 3A SUBSTRATE IN BEAGLE DOGS

EFFECT OF MULTIPLE DOSING OF KETOCONAZOLE ON PHARMACOKINETICS OF MIDAZOLAM, A CYTOCHROME P-450 3A SUBSTRATE IN BEAGLE DOGS 0090-9556/02/3001-63 68$3.00 DRUG METABOLISM AND DISPOSITION Vol. 30, No. 1 Copyright 2002 by The American Society for Pharmacology and Experimental Therapeutics 357/953757 DMD 30:63 68, 2002 Printed in

More information

Cytochrome P 450 Unique family of heme proteins present in bacteria, fungi, insects, plants, fish, mammals and primates. Universal oxygenases (oxygen-

Cytochrome P 450 Unique family of heme proteins present in bacteria, fungi, insects, plants, fish, mammals and primates. Universal oxygenases (oxygen- Cytochrome P 450 Biochemistry Department Cytochrome P 450 Unique family of heme proteins present in bacteria, fungi, insects, plants, fish, mammals and primates. Universal oxygenases (oxygen-utilizing

More information

Title. YOON, Seokjoo; MARUYAMA, Yutaka; KA FUJITA, Shoichi. Author(s) Issue Date /jjvr

Title. YOON, Seokjoo; MARUYAMA, Yutaka; KA FUJITA, Shoichi. Author(s) Issue Date /jjvr Title Application of FT-IR and ESR spectr study of CCl_4-induced peroxidation Author(s) YOON, Seokjoo; MARUYAMA, Yutaka; KA FUJITA, Shoichi Citation Japanese Journal of Veterinary Rese Issue Date 2000-02-29

More information

The metabolism of 1 - and 4-hydroxymidazolam by glucuronide conjugation is. largely mediated by UDP-glucuronosyltransferases 1A4, 2B4, and 2B7

The metabolism of 1 - and 4-hydroxymidazolam by glucuronide conjugation is. largely mediated by UDP-glucuronosyltransferases 1A4, 2B4, and 2B7 DMD Fast This article Forward. has not Published been copyedited on and August formatted. 16, The 2010 final version as doi:10.1124/dmd.110.035295 may differ from this version. The metabolism of 1 - and

More information

Metabolism of 1 - and 4-Hydroxymidazolam by Glucuronide Conjugation Is Largely Mediated by UDP-Glucuronosyltransferases 1A4, 2B4, and 2B7

Metabolism of 1 - and 4-Hydroxymidazolam by Glucuronide Conjugation Is Largely Mediated by UDP-Glucuronosyltransferases 1A4, 2B4, and 2B7 0090-9556/10/3811-2007 2013$20.00 DRUG METABOLISM AND DISPOSITION Vol. 38, No. 11 Copyright 2010 by The American Society for Pharmacology and Experimental Therapeutics 35295/3635725 DMD 38:2007 2013, 2010

More information

Note: During 30 minute incubation; proceed thru appropriate sections below (e.g. sections II, III and V).

Note: During 30 minute incubation; proceed thru appropriate sections below (e.g. sections II, III and V). LEGEND MAX β Amyloid x 40 LEGEND MAX β Amyloid x 40 ELISA Kit Components and Protocol Kit Components Capture Antibody Coated Plate 1 stripwell plate 1 40 Standard (2) 20μg vial 5X Wash Buffer 125mL Standard

More information

Kit for assay of thioredoxin

Kit for assay of thioredoxin FkTRX-02-V2 Kit for assay of thioredoxin The thioredoxin system is the major protein disulfide reductase in cells and comprises thioredoxin, thioredoxin reductase and NADPH (1). Thioredoxin systems are

More information

Serrata) Alkaline Phosphatase

Serrata) Alkaline Phosphatase Vol. 41, No. 5, April 1997 BIOCHEMISTRY and MOLECULAR BIOLOGY INTERNATIONAL Pages 951-959 An Essential Tryptophan Residue of Green Crab (Syclla Serrata) Alkaline Phosphatase Wen-Zhu Zheng 1, Qing-Xi Chen

More information

SPECIES AND SEX DIFFERENCES IN EXPRESSION OF FLAVIN-CONTAINING MONOOXYGENASE FORM 3 IN LIVER AND KIDNEY MICROSOMES

SPECIES AND SEX DIFFERENCES IN EXPRESSION OF FLAVIN-CONTAINING MONOOXYGENASE FORM 3 IN LIVER AND KIDNEY MICROSOMES 0090-9556/99/2701-0046 52$02.00/0 DRUG METABOLISM AND DISPOSITION Vol. 27, No. 1 Copyright 1999 by The American Society for Pharmacology and Experimental Therapeutics Printed in U.S.A. SPECIES AND SEX

More information

EVIDENCE FOR THE VALIDITY OF CORTISOL

EVIDENCE FOR THE VALIDITY OF CORTISOL 0090-9556/03/3111-1283 1287$7.00 DRUG METABOLISM AND DISPOSITION Vol. 31, No. 11 Copyright 2003 by The American Society for Pharmacology and Experimental Therapeutics 1129/1100488 DMD 31:1283 1287, 2003

More information

DAPSONE ACTIVATION OF CYP2C9-MEDIATED METABOLISM: EVIDENCE FOR ACTIVATION OF MULTIPLE SUBSTRATES AND A TWO-SITE MODEL

DAPSONE ACTIVATION OF CYP2C9-MEDIATED METABOLISM: EVIDENCE FOR ACTIVATION OF MULTIPLE SUBSTRATES AND A TWO-SITE MODEL 0090-9556/01/2907-1029 1034$3.00 DRUG METABOLISM AND DISPOSITION Vol. 29, No. 7 Copyright 2001 by The American Society for Pharmacology and Experimental Therapeutics 352/914007 DMD 29:1029 1034, 2001 Printed

More information

SUPPLEMENTARY INFORMATION. Bacterial strains and growth conditions. Streptococcus pneumoniae strain R36A was

SUPPLEMENTARY INFORMATION. Bacterial strains and growth conditions. Streptococcus pneumoniae strain R36A was SUPPLEMENTARY INFORMATION Bacterial strains and growth conditions. Streptococcus pneumoniae strain R36A was grown in a casein-based semisynthetic medium (C+Y) supplemented with yeast extract (1 mg/ml of

More information

Role of Human Liver Microsomal CYP3A4 and CYP2B6 in Catalyzing N-Dechloroethylation of Cyclophosphamide and Ifosfamide

Role of Human Liver Microsomal CYP3A4 and CYP2B6 in Catalyzing N-Dechloroethylation of Cyclophosphamide and Ifosfamide Biochemical Pharmacology, Vol. 59, pp. 961 972, 2000. ISSN 0006-2952/00/$ see front matter 2000 Elsevier Science Inc. All rights reserved. PII S0006-2952(99)00410-4 Role of Human Liver Microsomal CYP3A4

More information

Involvement of CYP2C8 and UGT1A9 in the metabolism of a novel gastroprokinetic agent, Z-338

Involvement of CYP2C8 and UGT1A9 in the metabolism of a novel gastroprokinetic agent, Z-338 Involvement of CYP2C8 and UGT1A9 in the metabolism of a novel gastroprokinetic agent, Z-338 S. Furuta 1, E. Kamada 1, T. Sugimoto 1, Y. Kawabata 1, X. C. Wu 2, J. Skibbe 3, E. Usuki 3, A. Parkinson 3 and

More information

<Supplemental information>

<Supplemental information> The Structural Basis of Endosomal Anchoring of KIF16B Kinesin Nichole R. Blatner, Michael I. Wilson, Cai Lei, Wanjin Hong, Diana Murray, Roger L. Williams, and Wonhwa Cho Protein

More information

In vitro metabolism of montelukast by Cytochrome P450s (CYPs) and UDPglucuronosyltransferases

In vitro metabolism of montelukast by Cytochrome P450s (CYPs) and UDPglucuronosyltransferases In vitro metabolism of montelukast by Cytochrome P450s (CYPs) and UDPglucuronosyltransferases (UGTs) Josiane de Oliveira Cardoso, Regina Vincenzi Oliveira, Jessica Bo Li Lu Zeruesenay Desta Department

More information

Role of CYP3A4 in Human Hepatic Diltiazem N-Demethylation: Inhibition of CYP3A4 Activity by Oxidized Diltiazem Metabolites 1

Role of CYP3A4 in Human Hepatic Diltiazem N-Demethylation: Inhibition of CYP3A4 Activity by Oxidized Diltiazem Metabolites 1 0022-3565/97/2821-0294$03.00/0 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Vol. 282, No. 1 Copyright 1997 by The American Society for Pharmacology and Experimental Therapeutics Printed in

More information

SUPPLEMENTAL INFORMATION

SUPPLEMENTAL INFORMATION SUPPLEMENTAL INFORMATION EXPERIMENTAL PROCEDURES Tryptic digestion protection experiments - PCSK9 with Ab-3D5 (1:1 molar ratio) in 50 mm Tris, ph 8.0, 150 mm NaCl was incubated overnight at 4 o C. The

More information

EFFECT OF PRETREATMENT WITH TRICRESYLPHOSPHATES AND PHENOBARBITAL ON THE METABOLISM AND TOXICITY OF PROCAINE IN RATS

EFFECT OF PRETREATMENT WITH TRICRESYLPHOSPHATES AND PHENOBARBITAL ON THE METABOLISM AND TOXICITY OF PROCAINE IN RATS EFFECT OF PRETREATMENT WITH TRICRESYLPHOSPHATES AND PHENOBARBITAL ON THE METABOLISM AND TOXICITY OF PROCAINE IN RATS Tetsuo SATOH' and Kayoko MOROI Department of Experimental Pharmacology, Research Institute

More information

COEXPRESSION OF CYTOCHROME P4502A6 AND HUMAN NADPH-P450 OXIDOREDUCTASE IN THE BACULOVIRUS SYSTEM

COEXPRESSION OF CYTOCHROME P4502A6 AND HUMAN NADPH-P450 OXIDOREDUCTASE IN THE BACULOVIRUS SYSTEM 0090-9556/97/2504-0399 405$02.00/0 DRUG METABOLISM AND DISPOSITION Vol. 25, No. 4 Copyright 1997 by The American Society for Pharmacology and Experimental Therapeutics Printed in U.S.A. COEXPRESSION OF

More information

Cytochrome P450 enzymes are involved in the metabolism of foreign substances

Cytochrome P450 enzymes are involved in the metabolism of foreign substances KHAN, MOHAMMAD MAZAMAL, M.S. Inhibition of Cytochrome P450 2E1 and Cytochrome P450 2A6 by Essential Oils: Tarragon (Artemisia dracunculus) and Basil (Ocimum basilicum). (2014) Directed by Dr. Gregory M.

More information

Supporting Information

Supporting Information Supporting Information Dauvillée et al. 10.1073/pnas.0907424106 Fig. S1. Iodine screening of the C. cohnii mutant bank. Each single colony was grown on rich-medium agar plates then vaporized with iodine.

More information

Chromatin IP (Isw2) Fix soln: 11% formaldehyde, 0.1 M NaCl, 1 mm EDTA, 50 mm Hepes-KOH ph 7.6. Freshly prepared. Do not store in glass bottles.

Chromatin IP (Isw2) Fix soln: 11% formaldehyde, 0.1 M NaCl, 1 mm EDTA, 50 mm Hepes-KOH ph 7.6. Freshly prepared. Do not store in glass bottles. Chromatin IP (Isw2) 7/01 Toshi last update: 06/15 Reagents Fix soln: 11% formaldehyde, 0.1 M NaCl, 1 mm EDTA, 50 mm Hepes-KOH ph 7.6. Freshly prepared. Do not store in glass bottles. 2.5 M glycine. TBS:

More information

EFFECTS OF ENDOGENOUS STEROIDS ON CYP3A4-MEDIATED DRUG METABOLISM BY HUMAN LIVER MICROSOMES

EFFECTS OF ENDOGENOUS STEROIDS ON CYP3A4-MEDIATED DRUG METABOLISM BY HUMAN LIVER MICROSOMES 0090-9556/02/3005-534 540$7.00 DRUG METABOLISM AND DISPOSITION Vol. 30, No. 5 Copyright 2002 by The American Society for Pharmacology and Experimental Therapeutics 582/977211 DMD 30:534 540, 2002 Printed

More information

Phospholipase D Activity of Gram-Negative Bacteria

Phospholipase D Activity of Gram-Negative Bacteria JOURNAL OF BACTERIOLOGY, Dec. 1975, p. 1148-1152 Copyright 1975 American Society for Microbiology Vol. 124, No. 3 Printed in U.S.A. Phospholipase D Activity of Gram-Negative Bacteria R. COLE AND P. PROULX*

More information

Nature Methods: doi: /nmeth Supplementary Figure 1

Nature Methods: doi: /nmeth Supplementary Figure 1 Supplementary Figure 1 Subtiligase-catalyzed ligations with ubiquitin thioesters and 10-mer biotinylated peptides. (a) General scheme for ligations between ubiquitin thioesters and 10-mer, biotinylated

More information

Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Pfizer Global Research and Development, Groton Laboratories, Groton, Connecticut

Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Pfizer Global Research and Development, Groton Laboratories, Groton, Connecticut 0090-9556/03/3105-606 611$7.00 DRUG METABOLISM AND DISPOSITION Vol. 31, No. 5 Copyright 2003 by The American Society for Pharmacology and Experimental Therapeutics 965/1059546 DMD 31:606 611, 2003 Printed

More information

Received December 14, 2009; accepted March 19, 2010

Received December 14, 2009; accepted March 19, 2010 0090-9556/10/3807-1211 1217$20.00 DRUG METABOLISM AND DISPOSITION Vol. 38, No. 7 Copyright 2010 by The American Society for Pharmacology and Experimental Therapeutics 31625/3591857 DMD 38:1211 1217, 2010

More information

The rabbit femoral artery was prepared and each arterial ring was permeabilized

The rabbit femoral artery was prepared and each arterial ring was permeabilized Online Supplement Nakmura et al. cgmp-dependent relaxation of smooth muscle Materials and Methods Measurement of tension The rabbit femoral artery was prepared and each arterial ring was permeabilized

More information

Microsomal Drug Oxidation

Microsomal Drug Oxidation Microsomal Drug Oxidation from a black box to a well understood multi-enzyme system Tsuneo Omura (Kyushu University) Discovery of Microsomes Fractionation of liver homogenates with an ultracentrifuge yielded

More information

IDENTIFICATION OF HUMAN LIVER CYTOCHROME P450 ENZYMES RESPONSIBLE FOR THE METABOLISM OF LONAFARNIB (SARASAR)

IDENTIFICATION OF HUMAN LIVER CYTOCHROME P450 ENZYMES RESPONSIBLE FOR THE METABOLISM OF LONAFARNIB (SARASAR) 0090-9556/06/3404-628 635$20.00 DRUG METABOLISM AND DISPOSITION Vol. 34, No. 4 Copyright 2006 by The American Society for Pharmacology and Experimental Therapeutics 7906/3102946 DMD 34:628 635, 2006 Printed

More information

Glucose Oxidase Pellets

Glucose Oxidase Pellets BIOTECHNOLOGY AND BIOENGINEERING VOL. XIX (1977) Glucose Oxidase Pellets INTRODUCTION Considerable world-wide interest has arisen in the use of immobilized enzymes as catalysts in industrial process and

More information

VALIDATION OF BUPROPION HYDROXYLATION AS A SELECTIVE MARKER OF HUMAN CYTOCHROME P450 2B6 CATALYTIC ACTIVITY

VALIDATION OF BUPROPION HYDROXYLATION AS A SELECTIVE MARKER OF HUMAN CYTOCHROME P450 2B6 CATALYTIC ACTIVITY 0090-9556/00/2810-1222 1230$03.00/0 DRUG METABOLISM AND DISPOSITION Vol. 28, No. 10 Copyright 2000 by The American Society for Pharmacology and Experimental Therapeutics 163/855917 DMD 28:1222 1230, 2000

More information

STEREOSELECTIVE METABOLISM OF LANSOPRAZOLE BY HUMAN LIVER CYTOCHROME P450 ENZYMES

STEREOSELECTIVE METABOLISM OF LANSOPRAZOLE BY HUMAN LIVER CYTOCHROME P450 ENZYMES 0090-9556/03/3110-1227 1234$7.00 DRUG METABOLISM AND DISPOSITION Vol. 31, No. 10 Copyright 2003 by The American Society for Pharmacology and Experimental Therapeutics 1086/1095069 DMD 31:1227 1234, 2003

More information

P450 CYCLE. All P450s follow the same catalytic cycle of;

P450 CYCLE. All P450s follow the same catalytic cycle of; P450 CYCLE All P450s follow the same catalytic cycle of; 1. Initial substrate binding 2. First electron reduction 3. Oxygen binding 4. Second electron transfer 5 and 6. Proton transfer/dioxygen cleavage

More information

DIFFERENCES IN THE INHIBITION OF CYTOCHROMES P450 3A4 AND 3A5 BY METABOLITE-INHIBITOR COMPLEX-FORMING DRUGS

DIFFERENCES IN THE INHIBITION OF CYTOCHROMES P450 3A4 AND 3A5 BY METABOLITE-INHIBITOR COMPLEX-FORMING DRUGS 0090-9556/04/3210-1083 1091$20.00 DRUG METABOLISM AND DISPOSITION Vol. 32, No. 10 Copyright 2004 by The American Society for Pharmacology and Experimental Therapeutics 1411/1174104 DMD 32:1083 1091, 2004

More information

Conversion of green note aldehydes into alcohols by yeast alcohol dehydrogenase

Conversion of green note aldehydes into alcohols by yeast alcohol dehydrogenase Conversion of green note aldehydes into alcohols by yeast alcohol dehydrogenase M.-L. Fauconnier 1, A. Mpambara 1, J. Delcarte 1, P. Jacques 2, P. Thonart 2 & M. Marlier 1 1 Unité de Chimie Générale et

More information

Effect of BD Matrigel Matrix Overlay and BD Matrigel Matrix Thin Coat on CYP450 Activities in Cryo Human Hepatocytes. Rongjun Zuo.

Effect of BD Matrigel Matrix Overlay and BD Matrigel Matrix Thin Coat on CYP450 Activities in Cryo Human Hepatocytes. Rongjun Zuo. Effect of BD Matrigel Matrix Overlay and BD Matrigel Matrix Thin Coat on CYP450 Activities in Cryo Human Hepatocytes Rongjun Zuo November 10, 2010 Topics Overview of Hepatocyte Products P450 Induction

More information

J. Nutr. Sci. Vitaminol., 38, , Note. in Tissues

J. Nutr. Sci. Vitaminol., 38, , Note. in Tissues J. Nutr. Sci. Vitaminol., 38, 517-521, 1992 Note A Simple Enzymatic Quantitative in Tissues Analysis of Triglycerides Hiroshi DANNO, Yuu JINCHO, Slamet BUDIYANTO, Yuji FURUKAWA, and Shuichi KIMURA Laboratory

More information

Sorafenib (free base, >99%) was obtained from Chemie Tek (Indianapolis, IN), and

Sorafenib (free base, >99%) was obtained from Chemie Tek (Indianapolis, IN), and Supplemental Methods Chemicals and Reagents Sorafenib (free base, >99%) was obtained from Chemie Tek (Indianapolis, IN), and isotopically-labeled 13 C- 2 H 3 -sorafenib (labeled atoms on N-methyl position)

More information

Naoya Takahashi, Keiya Hirota and Yoshitaka Saga* Supplementary material

Naoya Takahashi, Keiya Hirota and Yoshitaka Saga* Supplementary material Supplementary material Facile transformation of the five-membered exocyclic E-ring in 13 2 -demethoxycarbonyl chlorophyll derivatives by molecular oxygen with titanium oxide in the dark Naoya Takahashi,

More information

ROLE OF CYTOCHROME P-4502C9 IN IRBESARTAN OXIDATION BY HUMAN LIVER MICROSOMES

ROLE OF CYTOCHROME P-4502C9 IN IRBESARTAN OXIDATION BY HUMAN LIVER MICROSOMES 0090-9556/99/2702-0288 296$02.00/0 DRUG METABOLISM AND DISPOSITION Vol. 27, No. 2 Copyright 1999 by The American Society for Pharmacology and Experimental Therapeutics Printed in U.S.A. ROLE OF CYTOCHROME

More information

BIOCHEMICAL STUDIES ON CYTOCHROME P-450 SOLUBILIZED FROM LIVER MICROSOMES: PARTIAL PURIFICATION AND MECHANISM OF CATALYSIS*

BIOCHEMICAL STUDIES ON CYTOCHROME P-450 SOLUBILIZED FROM LIVER MICROSOMES: PARTIAL PURIFICATION AND MECHANISM OF CATALYSIS* BIOCHEMICAL STUDIES ON CYTOCHROME P-450 SOLUBILIZED FROM LIVER MICROSOMES: PARTIAL PURIFICATION AND MECHANISM OF CATALYSIS* Minor J. Coon, Theodore A. van der Hoeven, Robert M. Kaschnitz, and Henry W.

More information

Chris Bohl, Ph.D. Global Technical Support Manager- Products

Chris Bohl, Ph.D. Global Technical Support Manager- Products Chris Bohl, Ph.D. Global Technical Support Manager- Products cbohl1@xenotechllc.com Sekisui XenoTech Overview GLP-compliant in vitro ADME-DMPK CRO founded in 1994 at the University of Kansas Medical Center

More information